The review examines the vital role of prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in the diagnosis, staging, and treatment of prostate cancer (PCa). It focuses on the superior diagnostic abilities of PSMA PET/CT for identifying both nodal and distant PCa, and its potential as a prognostic indicator for biochemical recurrence and overall survival. Additionally, we focused on the variability of PSMA's expression and its impact on personalised treatment, particularly the use of [177Lu] Lu-PSMA-617 radioligand therapy. This review emphasises the essential role of PSMA PET/CT in enhancing treatment approaches, improving patient outcomes, and reducing unnecessary interventions, positioning it as a key element in personalised PCa management.
Cancers. 2024 Feb 26*** epublish ***
Haidar Al Saffar, David C Chen, Carlos Delgado, Jacob Ingvar, Michael S Hofman, Nathan Lawrentschuk, Marlon Perera, Declan G Murphy, Renu Eapen
Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC 3052, Australia., School of Medicine and Health Sciences, Tecnologico de Monterrey, Monterrey 64849, Mexico., Prostate Cancer Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, VIC 3052, Australia.